Connecting TDP-43 Pathology to Molecular Profiles in Neurodegeneration
Official title: Connecting TDP-43 Pathology to the Molecular Profiles of Neurodegeneration
Funded at New York University School of Medicine · NIH-11606642 · Data updated 2026-11-12
This grant explores how specific molecular patterns in brain tissue relate to ALS and Alzheimer’s disease features, aiming to improve understanding of disease subtypes and progression.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 15, 2020 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $518,509 |
| NIH project number | 2R56NS118570-03A1 |
| Project ID | NIH-11606642 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with ALS, ALS/FTD spectrum conditions, or Alzheimer’s disease-related neurodegeneration who have tissue or data contributing to molecular subtype analyses.
✕Less likely to help
Patients not fitting the ALS/FTD spectrum or without access to tissue/data contributing to molecular profiling may see limited direct benefit.
What this research studies
A team at NYU Langone uses neurogenomics, RNA biology, and AI to study tissue samples from people with ALS/FTD and related disorders. They previously identified distinct molecular subtypes in ALS/FTD and are now examining how these subtypes relate to how the disease starts, progresses, and presents clinically. The project examines whether these molecular patterns could help tailor future clinical trials by grouping patients by underlying biology. The work builds on prior findings replicated by independent groups and seeks to clarify whether subtypes reflect disease stage or separate disease drivers.
Why it matters
Potential benefit: If successful, patients could benefit from more precise disease classification that may guide future personalized treatments and trial eligibility.
How similar studies have gone: Previous studies identified ALS/FTD molecular subtypes and replicated by independent groups, supporting the approach's potential validity.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Gale Hammell, Molly — New York University School of Medicine
- Study coordinator: Gale Hammell, Molly
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.